ENCell Co Ltd
KOSDAQ:456070
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ENCell Co Ltd
Current Portion of Long-Term Debt
ENCell Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ENCell Co Ltd
KOSDAQ:456070
|
Current Portion of Long-Term Debt
₩1.4B
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Current Portion of Long-Term Debt
₩173.6B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Current Portion of Long-Term Debt
₩430.2m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Current Portion of Long-Term Debt
₩285.8m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
24%
|
CAGR 10-Years
-18%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Current Portion of Long-Term Debt
₩46.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
121%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Current Portion of Long-Term Debt
₩1.1B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
ENCell Co Ltd
Glance View
ENCell Co Ltd is a KR-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-08-23. ENCell Co Ltd is a Korea-based company principally engaged in the development and research of new drugs. The firm is principally engaged in the development and research of cell and gene-based biopharmaceuticals. The firm is also engaged in the provision of biopharmaceutical quality testing services. In addition, the Company is engaged in the biopharmaceutical consignment production business.
See Also
What is ENCell Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.4B
KRW
Based on the financial report for Dec 31, 2024, ENCell Co Ltd's Current Portion of Long-Term Debt amounts to 1.4B KRW.
What is ENCell Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-59%
Over the last year, the Current Portion of Long-Term Debt growth was 6%. The average annual Current Portion of Long-Term Debt growth rates for ENCell Co Ltd have been -59% over the past three years .
